Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
A Meta-Analysis
Jeff S. Healey, MD*,*,
Adrian Baranchuk, MD*,
Eugene Crystal, MD ,
Carlos A. Morillo, MD*,
Michael Garfinkle, BA ,
Salim Yusuf, MD, PhD* and
Stuart J. Connolly, MD*
* Population Health Research Institute, McMaster University, and Hamilton Health Sciences, Hamilton, Ontario, Canada
University of Toronto, Toronto, Ontario, Canada.

View larger version (31K):
[in a new window]
|
Figure 1 Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). CI = confidence interval; RR = relative risk.
|
|

View larger version (36K):
[in a new window]
|
Figure 2 Prevention of atrial fibrillation in various patient populations. Abbreviations as in Figure 1.
|
|
|